Skip to content


Who we are

The Malaria Infection Study in Thailand (MIST) is a programme of research to develop a model to safely and quickly test vaccine and drug candidates to treat Plasmodium vivax malaria. MIST is a collaborative programme by the Malaria Vivax Research Unit (MVRU) and Mahidol Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, and funded by Wellcome Trust, UK.

What we do

MIST is committed to accelerating the path to a malaria cure by initiating Thailand’s first human infection study. The research trial will involve carefully infecting healthy adult volunteers with a controlled number of malaria parasites. These small numbers of parasites are not meant to make the volunteers ill, but will allow researchers to study immuno-response to the parasite in a carefully controlled laboratory setting before symptoms develop.

Our team of world-class researchers brings decades of experience conducting successful human infection studies in many countries, including the USA, Australia, and the UK. 

These studies are important but incomplete. Because those countries do not have malaria, it is unclear if the results can be extrapolated to countries where malaria is present. The MIST trial represents a major step forward that will allow researchers to study new drugs’ efficacy in a population where malaria occurs naturally.

Why us?

The faculty of Tropical Medicine at Mahidol University has been a world-leader in the research and treatment of tropical diseases for over a half-century, and is home to state-of-art research hospital facilities, diagnostic laboratories, and a top-rated clinical research centre. Working in collaboration with Oxford University and the Wellcome Trust, the MIST team is combining international expertise with the well-established infrastructure.

New scientific data obtained from MIST will enable us to test and develop new candidate vaccines, bringing us closer to the eradication of P. vivax in Thailand and across Southeast Asia. To eliminate malaria would be a transformative accomplishment on behalf of the health and welfare of people across the world.

Assoc. Prof. Pratap Singhasivanon, previous Dean at the Faculty of Tropical Medicine, Mahidol University

Our partners

  • Mahidol Vivax Research Unit
  • MORU
  • Mahidol University
  • Wellcome Trust